-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Assumes Nurix Therapeutics at Buy, Raises Price Target to $30

Benzinga·11/24/2025 18:13:30
Listen to the news
Truist Securities analyst Gregory Renza assumes Nurix Therapeutics (NASDAQ:NRIX) with a Buy rating and raises Price Target to $30.